Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX

被引:35
|
作者
Rea, Domenica [1 ]
del Vecchio, Vitale [1 ]
Palma, Giuseppe [1 ]
Barbieri, Antonio [1 ]
Falco, Michela [1 ]
Luciano, Antonio [1 ]
De Biase, Davide [2 ]
Perdona, Sisto [3 ]
Facchini, Gaetano [4 ]
Arra, Claudio [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori Fdn G Pascale, IRCCS, Dept Expt Oncol, Anim Facil Unit, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dept Vet Med & Anim Prod, Via Delpino 1, I-80137 Naples, Italy
[3] Ist Nazl Studio & Cura Tumori Fdn G Pascale, IRCCS, Dept Urol, I-80131 Naples, Italy
[4] Ist Nazl Studio & Cura Tumori Fdn G Pascale, IRCCS, Dept Urogynaecol Oncol, Div Med Oncol, I-80131 Naples, Italy
关键词
SUBRENAL CAPSULE XENOGRAFTS; GROWTH-FACTOR-I; ANDROGEN RECEPTOR; CELL-LINES; INTRAEPITHELIAL NEOPLASIA; TUMOR XENOGRAFTS; GENE-EXPRESSION; CONDITIONAL DELETION; TARGETED THERAPY; HUMANIZED MICE;
D O I
10.1155/2016/9750795
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Despite the advancement of clinical and preclinical research on PCa, which resulted in the last five years in a decrement of disease incidence by 3-4%, it remains the most frequent cancer in men and the second for mortality rate. Based on this evidence we present a brief dissertation on numerous preclinical models, comparing their advantages and disadvantages; among this we report the PDX mouse models that show greater fidelity to the disease, in terms of histopathologic features of implanted tumor, gene and miRNA expression, and metastatic pattern, well describing all tumor progression stages; this characteristic encourages the translation of preclinical results. These models become particularly useful in meeting the need of new treatments identification that eradicate PCa bone metastases growing, clarifying pathway of angiogenesis, identifying castration-resistant stem-like cells, and studying the antiandrogen therapies. Also of considerable interest are the studies of 3D cell cultures derived from PDX, which have the ability to maintain PDX cell viability with continued native androgen receptor expression, also showing a differential sensitivity to drugs. 3D PDX PCa may represent a diagnostic platform for the rapid assessment of drugs and push personalized medicine. Today the development of preclinical models in vitro and in vivo is necessary in order to obtain increasingly reliable answers before reaching phase III of the drug discovery.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Patient-derived xenograft (PDX) models in basic and translational breast cancer research
    Dobrolecki, Lacey E.
    Airhart, Susie D.
    Alferez, Denis G.
    Aparicio, Samuel
    Behbod, Fariba
    Bentires-Alj, Mohamed
    Brisken, Cathrin
    Bult, Carol J.
    Cai, Shirong
    Clarke, Robert B.
    Dowst, Heidi
    Ellis, Matthew J.
    Gonzalez-Suarez, Eva
    Iggo, Richard D.
    Kabos, Peter
    Li, Shunqiang
    Lindeman, Geoffrey J.
    Marangoni, Elisabetta
    McCoy, Aaron
    Meric-Bernstam, Funda
    Piwnica-Worms, Helen
    Poupon, Marie-France
    Reis-Filho, Jorge
    Sartorius, Carol A.
    Scabia, Valentina
    Sflomos, George
    Tu, Yizheng
    Vaillant, Francois
    Visvader, Jane E.
    Welm, Alana
    Wicha, Max S.
    Lewis, Michael T.
    CANCER AND METASTASIS REVIEWS, 2016, 35 (04) : 547 - 573
  • [2] Patient-derived xenograft (PDX) models in basic and translational breast cancer research
    Lacey E. Dobrolecki
    Susie D. Airhart
    Denis G. Alferez
    Samuel Aparicio
    Fariba Behbod
    Mohamed Bentires-Alj
    Cathrin Brisken
    Carol J. Bult
    Shirong Cai
    Robert B. Clarke
    Heidi Dowst
    Matthew J. Ellis
    Eva Gonzalez-Suarez
    Richard D. Iggo
    Peter Kabos
    Shunqiang Li
    Geoffrey J. Lindeman
    Elisabetta Marangoni
    Aaron McCoy
    Funda Meric-Bernstam
    Helen Piwnica-Worms
    Marie-France Poupon
    Jorge Reis-Filho
    Carol A. Sartorius
    Valentina Scabia
    George Sflomos
    Yizheng Tu
    François Vaillant
    Jane E. Visvader
    Alana Welm
    Max S. Wicha
    Michael T. Lewis
    Cancer and Metastasis Reviews, 2016, 35 : 547 - 573
  • [3] Use of nude mouse xenograft models in prostate cancer research
    van Weerden, WM
    Romijn, JC
    PROSTATE, 2000, 43 (04): : 263 - 271
  • [4] Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research
    Schuette, Ute
    Bisht, Savita
    Brossart, Peter
    Feldmann, Georg
    EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (01) : 33 - 48
  • [5] Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research
    Irtenkauf, Susan M.
    Sobiechowski, Susan
    Hasselbach, Laura A.
    Nelson, Kevin K.
    Transou, Andrea D.
    Carlton, Enoch T.
    Mikkelsen, Tom
    Decarvalho, Ana C.
    COMPARATIVE MEDICINE, 2017, 67 (04) : 300 - 314
  • [6] Patient-derived xenograft (PDX) models, applications and challenges in cancer research
    Abdolahi, Shahrokh
    Ghazvinian, Zeinab
    Muhammadnejad, Samad
    Saleh, Mahshid
    Asadzadeh Aghdaei, Hamid
    Baghaei, Kaveh
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [7] Patient-derived xenograft (PDX) models, applications and challenges in cancer research
    Shahrokh Abdolahi
    Zeinab Ghazvinian
    Samad Muhammadnejad
    Mahshid Saleh
    Hamid Asadzadeh Aghdaei
    Kaveh Baghaei
    Journal of Translational Medicine, 20
  • [8] A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine
    Collins, Anne T.
    Lang, Shona H.
    PEERJ, 2018, 6
  • [9] A patient-derived xenograft (PDX) platform for cancer translational, precision medicine and health disparity research
    Pan, Chong-Xian
    Zhang, Hongyong
    Ma, Ai-Hong
    Zeng, Shuxiong
    Zimmermann, Maike
    Tepper, Clifford
    Henderson, Paul
    Carvajal-Carmona, Luis
    Gandour-Edwards, Regina
    Chen, Moon
    Airhart, Susan
    Whtie, Ralph de Vere
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Prostate cancer xenograft models
    Romijn, JC
    PROSTATE AND RENAL CANCER, BENIGN PROSTATIC HYPERPLASIA, ERECTILE DYSFUNCTION AND BASIC RESEARCH: AND UPDATE, 2003, : 172 - 179